Sudeep Pharma Limited has disclosed that its wholly owned subsidiary has completed a significant land acquisition in Gujarat to establish a new manufacturing facility. The transaction, valued at ₹20.97 crores, represents a strategic expansion into battery-grade materials production.

Land Acquisition Details

Sudeep Advanced Materials Private Limited has purchased leasehold rights to land in Dahej, Gujarat from DCM Shriram Fine Chemicals Limited. The acquisition involves a substantial industrial plot within the Gujarat Industrial Development Corporation (GIDC) industrial estate.

Manufacturing Facility Purpose

The acquired land will be utilized to establish a commercial manufacturing facility focused on battery-grade precursor materials. The primary product to be manufactured at this facility will be iron phosphate, which is a crucial component in battery technology. This expansion indicates the company's strategic entry into the growing battery materials sector.

Transaction Structure

The land purchase involves leasehold rights rather than outright ownership, which is common for industrial plots within GIDC estates. The transaction consideration of ₹20.97 crores excludes transfer charges and other applicable duties that may be incurred during the completion process.

Regulatory Compliance

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transaction completion remains subject to obtaining necessary approvals, consents, and permissions from concerned authorities. The company has confirmed that this transaction does not constitute a related party transaction and involves no connections with promoter groups.

Strategic Implications

This land acquisition represents Sudeep Pharma's diversification strategy through its subsidiary into the battery materials manufacturing sector. The focus on iron phosphate production aligns with the growing demand for battery-grade materials in various industrial applications. The Dahej location provides strategic advantages due to its established industrial infrastructure and connectivity within the GIDC framework.

Sudeep Pharma Limited has completed the formal update of its Corporate Identification Number (CIN) and company status on the Ministry of Corporate Affairs (MCA) website following its stock exchange listing. The pharmaceutical company informed the exchanges about this administrative update through a regulatory filing dated January 16, 2026.

CIN Update Details

The company's application to the Registrar of Companies, Gujarat, for updating its master data has been processed successfully. The changes reflect the company's transition from an unlisted to a listed entity following its debut on the stock exchanges.

Company Profile and Listing Information

Sudeep Pharma Limited successfully listed on both BSE and NSE on November 28, 2025. The company, incorporated on December 21, 1989, operates in the pharmaceutical sector and is registered under the ROC Ahmedabad jurisdiction.

Financial and Compliance Status

The updated MCA master data reveals key financial parameters and compliance status of the company. Sudeep Pharma maintains active compliance status and operates as a public limited company.

Administrative Update Process

The CIN update process was initiated following the company's listing on the stock exchanges. Company Secretary and Compliance Officer Dimple Mehta signed the intimation letter digitally, confirming the completion of the administrative formalities. The updated master data from the MCA website has been submitted to both BSE and NSE for their records.

The change in CIN prefix from 'U' to 'L' is a standard procedure that indicates the company's listed status, providing transparency to stakeholders and regulatory authorities about the company's current market position.